0001723059 false 0001723059 2023-06-06 2023-06-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

June 6, 2023

(Date of Report)

 

BIO ESSENCE CORP.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

 

California   333-232839   94-3349551

(STATE OR OTHER JURISDICTION OF

INCORPORATION OR ORGANIZATION)

   (COMMISSION FILE NO.)   (IRS EMPLOYEE
IDENTIFICATION NO.)

 

8 Studebaker Drive, Irvine, California 92618
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

(949) 706-9966
(ISSUER TELEPHONE NUMBER)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 8.01 Other Events.

 

On May 31, 2023, the Board of Directors of Bio Essence Corp. (the “Company”), approved a debt-to-equity conversion. The Company’s operations over the past several years have, in large part, been funded by the Company’s Chief Executive Officer Yin Yan. As of May 31, 2023, the Company’s obligation to Ms. Yan totaled $2,500,000. In exchange for a full release of the debt owed to Ms. Yan, the Company and Ms. Yan agreed to a debt conversion whereby Ms. Yan receives 5,000,000 shares of the Company’s common stock in exchange for retirement of the $2,500,000 debt. The Board of Directors of the Company executed the Consent Resolution, attached here as an exhibit between June 1, 2023 and June 2, 2023.

 

In exchange for the issuance of common stock described herein, Ms. Yan executed a Release, attached to the Consent Resolution as “Exhibit A” waiving any claims associated with the debt owed to Ms. Yan by the Company. The Consent Resolution and Release are attached hereto as exhibits.

 

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

 

Exhibit No.   Description
99.1  

Consent of Board of Directors (and Exhibit)

104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIO ESSENCE CORP.
   
  /s/ Yin Yan
  By: Yin Yan
  Its: Chief Executive Officer
  Dated: June 6, 2023

 

 

2
 

Bio Essence (PK) (USOTC:BIOE)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more Bio Essence (PK) Charts.
Bio Essence (PK) (USOTC:BIOE)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more Bio Essence (PK) Charts.